BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia

Caliway Advances Global Phase 3 Programme For CBL 514 Following U.S. FDA IND Clearance

Asia-Pacific Phase 2 Study CBL-0206 Also Approved by Australia HREC and Taiwan TFDA, Accelerating Global Dual-Track Strategy ...

May 26, 2026 | News

Registrar Corp And U.S. Commercial Service Strengthen Support For Australian Exporters Entering U.S. Market

Registrar Corp, the global leader in U.S. Food and Drug Administration (FDA) regulatory compliance services, partnered with the U.S. Commercial Servic...

May 26, 2026 | Regulatory

Scribe Therapeutics Gains Australian Clearance To Begin First Human Trial Of STX 1150 For Hypercholesterolemia

Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to exte...

May 26, 2026 | News

HaemaLogiX Opens Phase 1 KOALA Trial Of KMCAR T Cell Therapy For Relapsed Multiple Myeloma

Phase 1 KOALA clinical trial evaluating KMCAR™ T-cell therapy in relapsed/refractory kappa-restricted multiple myeloma now open for patient enrolme...

May 21, 2026 | News

Racura Oncology Receives Positive Safety Review Committee Recommendation To Advance CPACS Trial In Advanced Solid Tumours

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced soli...

May 18, 2026 | News

Australia’s NinaMED Launches With $13.75 Million Financing To Advance Global Commercialisation Of Non Invasive OAB Therapy

US$13.75M financing completed to accelerate clinical pathway and global commercialisation Establishment of NinaMED Pty Ltd, a new Australian medtech com...

May 15, 2026 | News

Australia Registers PEDMARQSI As First Approved Therapy To Prevent Cisplatin Related Hearing Loss In Children

PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 ...

May 07, 2026 | News

VectorBuilder Secures European Patent For MiniVec Plasmid System Advancing Genetic Medicine Development

Small by design, built for the demands of modern genetic medicine across gene therapy, cell therapy, and vaccines VectorBuilder, a global leader in ...

May 06, 2026 | News

EnGeneIC Doses First Patient In Trial Targeting Recurrent Glioblastoma

EnGeneIC announced that the first patient has been dosed in its clinical trial evaluating EnGeneIC’s investigational EGFR-targeted EDV™ (EnGene...

May 05, 2026 | News

Acrux Advances Female Testosterone Therapy To Phase III To Address HSDD Treatment Gap

Massive unmet need for Hypoactive Sexual Desire Disorder treatments addressed by new Female Testosterone product Phase I and II clinical trials complete...

April 30, 2026 | News

SynbioTech Probiotic Strain Shows Potential In Uric Acid Regulation Through Multi Mechanism Action

SynbioTech announced that its Lactiplantibacillus plantarum FS4722 (L. plantarum FS4722), a probiotic strain isolated from traditional Chine...

April 23, 2026 | News

Kazia Therapeutics Expands Oncology Pipeline With SETDB1 Targeted Epigenetic Platform

Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment re...

April 15, 2026 | News

Telix And Regeneron Pharmaceuticals Partner To Advance Next Generation Radiopharmaceutical Therapies

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Collabora...

April 14, 2026 | News

Shanghai Ark Biopharmaceutical Advances First In Human Trial Of Long Acting Influenza Therapy AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a nove...

April 13, 2026 | News

Stay Connected